AusperBio
Develops oligonucleotide therapeutics targeting chronic hepatitis B
$120MSeries C
Role not disclosedLoading investors…
Activity from announced rounds
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases
Pitching HanKang Capital? Send the deck from a free RoundOS data room and see which pages they read.